TABLE 1.

Classification of new AAV2 pore mutants

Mutation(s)	Mean value ± SDa			Classe
	Assembly reduction with respect to wtb	Packaging reduction with respect to wtc	Infectivity reduction with respect to wtd
D327A	4.4 ± 2.9f	1.0 ± 0.2	11.3 ± 6.3	I
T329A/T330A	7.8 ± 4.1f	47.1 ± 8.8f	8.3E2 ± 2.7E2f	P+I
V221W	40.8 ± 20.1f	2.9 ± 0.4f	1.1E2 ± 0.5E2f	A+P+I
N334W	UD	UD	UD	A
L336W	4.9 ± 2.6f	4.7 ± 0.6f	2.0E2 ± 0.7E2f	P+I
D219A/L336W	6.7 ± 4.4f	2.6 ± 0.4f	2.1E2 ± 0.3E2f	P+I
S338A/V221W	UD	UD	UD	A

^aValues are means plus or minus standard deviations from at least four independent experiments. UD, undetectable.

^bAssembly is expressed as the number of assembled capsids, as determined by a capsid ELISA (14), and compared to the capsid titer of wt AAV2.

^cPackaging was measured as the ratio of capsids to viral genomes and compared to the ratio for wt AAV2. The number of assembled capsids was determined by a capsid ELISA (14); packaged DNA was quantified by a dot blot assay.

^dInfectivity is expressed as the ratio of genomes to infectious units and compared to the ratio for wt AAV2. Packaged DNA was measured by a dot blot assay; infectious AAV2 particles were quantified by a dot blot replication assay.

^eMutants were classified according to their defects as follows: A, assembly (more than 10-fold reduction compared to that in the wt); I, infectivity (more than 10-fold reduction compared to that in the wt); P, packaging (more than 2-fold reduction compared to that in the wt).

^fIn comparison with the wt, the P value was <0.05.